- Conditions
- Acute Kidney Injury, Fluid Overload, Hypotension, Dialysis; Complications, Critical Illness
- Interventions
- Restrictive UFnet Rate Strategy, Liberal UFnet Rate Strategy
- Procedure
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • Pittsburgh, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 695
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Renal Insufficiency, Chronic
- Interventions
- 6R-BH4, 6R-BH4 placebo, Folic acid, Exercise training, Stretching, Histidine and beta-alanine supplementation, Histidine and beta-alanine placebo
- Drug · Other · Dietary Supplement
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Decatur, Georgia
- Conditions
- Anemia, Dialysis-Dependent Chronic Kidney Disease
- Interventions
- Vadadustat, Darbepoetin alfa
- Drug
- Lead sponsor
- Akebia Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,554 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 127
- States / cities
- Huntsville, Alabama • Mesa, Arizona • Pine Bluff, Arkansas + 95 more
- Conditions
- Hypertension in Pregnancy
- Interventions
- Remote (text based) surveillance
- Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Prader-Willi Syndrome
- Interventions
- Listening Project Protocol
- Behavioral
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 13 Years to 25 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Brewster, Massachusetts
- Conditions
- Elevated Blood Pressure, Pregnancy Induced Hypertension
- Interventions
- Nifedipine, Labetalol
- Drug
- Lead sponsor
- Marshall University
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 2 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Huntington, West Virginia
- Conditions
- Hypertension, Pregnancy-Induced, Pre-eclampsia
- Interventions
- Ibuprofen, Acetaminophen
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Chronic Kidney Disease
- Interventions
- Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD, Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD
- Drug
- Lead sponsor
- Mineralys Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 44
- States / cities
- Glendale, Arizona • Phoenix, Arizona • Chula Vista, California + 39 more
- Conditions
- Chronic Kidney Disease
- Interventions
- Self-management of BP medications, Self-monitoring of home BP
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Diabetic Nephropathies, Kidney Failure, Chronic, Diabetes Mellitus Type 1, Heart Failure
- Interventions
- Sotagliflozin, Placebo
- Drug
- Lead sponsor
- Alessandro Doria
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 13
- States / cities
- Stanford, California • Aurora, Colorado • Orlando, Florida + 10 more
- Conditions
- Coronary Artery Disease, Diabetes Mellitus
- Interventions
- ticagrelor
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Chronic Kidney Disease, Hypertension
- Interventions
- Protocolized, pharmacist-delivered CKD Action Plan
- Other
- Lead sponsor
- Geisinger Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Danville, Pennsylvania
- Conditions
- Acute Kidney Injury, Ischemia Reperfusion Injury
- Interventions
- Valproic Acid Solution, Isotonic saline solution
- Drug
- Lead sponsor
- Westat
- Other
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Seattle, Washington
- Conditions
- Turner's Syndrome
- Interventions
- Estrogen
- Drug
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- 8 Years to 12 Years · Female only
- Enrollment
- 260 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 1990
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Cardiovascular Disease, Chronic Kidney Disease
- Interventions
- angiotensin converting enzyme inhibitor, lisinopril
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 60 Years to 89 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Renal Artery Stenosis
- Interventions
- Gadoterate meglumine (Dotarem), Time of Flight Magnetic Resonance Angiography
- Drug · Other
- Lead sponsor
- Guerbet
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Bloomington, Indiana
- Conditions
- End Stage Renal Disease, Hyperhomocysteinemia
- Interventions
- cyanocobalamin, folic acid, pyridoxine
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 21 Years to 89 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2000
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Chronic Kidney Diseases, Cardiovascular Diseases
- Interventions
- Not listed
- Lead sponsor
- University of Miami
- Other
- Eligibility
- Up to 10 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2029
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Cardiomyopathy, Pregnancy-Associated Cardiomyopathy, Heart Failure
- Interventions
- Not listed
- Lead sponsor
- St. Vincent's Medical Center
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Infant, Premature, Erythropoietin, Brain Injury, Intraventricular Hemorrhage, Periventricular Leukomalacia, Neurodevelopmental Outcomes, Randomized Clinical Trial
- Interventions
- Erythropoietin, Saline placebo
- Drug
- Lead sponsor
- Atlantic Health System
- Other
- Eligibility
- Up to 24 Hours
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Morristown, New Jersey
- Conditions
- Cancer
- Interventions
- graft versus host disease prophylaxis/therapy, fluorescence in situ hybridization, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, in vitro-treated bone marrow transplantation, management of therapy complications
- Biological · Genetic · Other + 1 more
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 8
- States / cities
- Cleveland, Ohio
- Conditions
- Carcinoma, Renal Cell
- Interventions
- DFF332, RAD001, PDR001, NIR178
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 5
- States / cities
- Duarte, California • Boston, Massachusetts • St Louis, Missouri + 2 more
- Conditions
- Postpartum Preeclampsia, Hypertension in Pregnancy
- Interventions
- Labetalol Oral Tablet, NIFEdipine ER
- Drug
- Lead sponsor
- Nebraska Methodist Health System
- Other
- Eligibility
- 19 Years and older · Female only
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- White Matter Injury, Brain Injury, Fetus and Neonate, Neonatal Brain Injury, Periventricular Leukomalacia, Periventricular White Matter Abnormalities
- Interventions
- Clemastine fumarate
- Drug
- Lead sponsor
- Bridget LaMonica Ostrem, M.D., Ph.D.
- Other
- Eligibility
- 3 Weeks to 20 Weeks
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- San Francisco, California